stockrowDr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.
- Revenue
- −10.1%
- EPS
- −36.8%
- Free cash flow
- −70.5%
- Total debt
- +14.1%
Quarter to September 2026, against a year earlier
Follow RDY
Alert me
Dr. Reddy's Laboratories Ltd (RDY) P/S ratio
As of 5 November 2026, Dr. Reddy's Laboratories Ltd (RDY) trades at a P/S ratio of 3.6×. Over the past ten years it has ranged from 2.0× (August 2017) to 18.6× (October 2024); the current reading is higher than 69% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.1× and in line with the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2026 | 3.2× | 11.71% |
| FY2025 | 2.9× | (21.51%) |
| FY2024 | 3.7× | 16.23% |
| FY2023 | 3.2× | (3.43%) |
| FY2022 | 3.3× | (16.63%) |
| FY2021 | 3.9× | 35.93% |
| FY2020 | 2.9× | (4.49%) |
| FY2019 | 3.0× | 22.73% |
| FY2018 | 2.5× | (20.06%) |
| FY2017 | 3.1× | (6.65%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 3.2× | (4.59%) |
| Jun 2026 | 3.3× | 2.57% |
| Mar 2026 | 3.2× | 8.45% |
| Dec 2025 | 3.0× | 0.66% |
| 43 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| VTRS Viatris Inc. compare | 1.5× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 2.0× |
| HIMS Hims & Hers Health, Inc. compare | 2.2× |
| ELAN Elanco Animal Health Incorporated compare | 2.4× |
| RDY Dr. Reddy's Laboratories Ltd | 3.6× |
| LNTH Lantheus Holdings, Inc. compare | 4.2× |
| ALKS Alkermes plc compare | 4.3× |
| NBIX Neurocrine Biosciences, Inc. compare | 4.4× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 7.3× |
| Drug Manufacturers Specialty & Generic industry median | 2.1× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on RDY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement